Skip to content

Impact of Thyroid Treatment on Ovarian Function and Pregnancy Outcomes in Women with Differentiated Thyroid Cancer

Impact of Thyroid Treatment on Ovarian Function and Pregnancy Outcomes in Women with Differentiated Thyroid Cancer: a Prospective Cohort Study

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06845098
Enrollment
300
Registered
2025-02-25
Start date
2025-02-20
Completion date
2028-12-31
Last updated
2025-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Gland

Brief summary

This project aims to study the effects of different types of thyroid surgery and RAIT on ovarian function and pregnancy outcomes of DTC women of childbearing age, analyze possible risk factors, and assess whether potential risk factors such as age, thyroid stimulating hormone (TSH) levels and positive thyroid antibodies are related to ovarian hypofunction and adverse pregnancy outcomes.

Detailed description

1\) Screen the patients in the group according to the inclusion and exclusion criteria and sign the informed consent form (a total of 300 patients were included). Fill in the questionnaire after joining the group. 2) Physical examination of patients before treatment (measure height, weight, waist circumference, hip circumference, body fat distribution and percentage); thyroid function test (thyroid B-ultrasound, TSH, FT3, FT4, TPO-Ab, TG-Ab); baseline ovarian function test (AMH, menstruation 1-3 days Six hormones, observe the ovarian condition and the number of sinus follicles through vaginal B-ultrasound); leave blood for scientific research: 2 tubes of coagulation (serum), 1 tube of whole blood, -80℃ freeze. 3) Different types of thyroid surgery (thyroid unilateral lobe + isthmus resection, total thyroidectomy, total thyroidectomy + RAIT) are treated. 4) 3, 6, 12 and 24 months after treatment, the patients in the group should be followed up on ovarian and thyroid function, including physical examination (measurement of height, weight, waist circumference, hip circumference, body fat distribution and percentage); thyroid function testing (thyroid B-ultrasound, TSH, FT3, FT4, TPO-Ab, T G-Ab); ovarian function test (AMH, six items of sex hormones for 1-3 days of menstruation, observation of ovarian conditions and the number of sinus follicles through vaginal B-ultrasound); retention of blood for scientific research: 2 tubes (serum) of blood-promoting blood, 1 tube of whole blood, -80℃ freezing; record adverse reactions and combined medication. 5) If the patient in the group is pregnant during the follow-up period, the pregnancy follow-up shall be carried out according to the CRF table items at 2, 4, 12, 28 and 37 weeks of pregnancy respectively; delivery follow-up shall be carried out on the day of delivery and 6 weeks after delivery. 6) After the research, collect and sort out data for statistical analysis, summarize and sort out the results and publish them in professional journals in relevant fields in the form of papers.

Interventions

PROCEDURETotal thyroidectomy

Total thyroidectomy

PROCEDURETotal thyroidectomy + RAIT

Total thyroidectomy + RAIT

PROCEDUREThyroid one-sided lobe + isthmus resection

Thyroid one-sided lobe + isthmus resection

Sponsors

Zhejiang Provincial People's Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

1. Age 20-45 years old; 2. Premenopausal women whose thyroid B-ultrasound + surgical pathology is clearly differentiated thyroid cancer (papillar thyroid cancer or follicular thyroid cancer); 3. TNM stage is in stage I (T1-3, N0 or N1, M0); 4. Treatment of thyroid tumor resection: unilateral lobe of the thyroid + isthmus resection, total thyroidectomy, total thyroidectomy + RAIT.

Exclusion criteria

1. Patients with malignant tumors in other parts or low undifferentiated thyroid cancer; 2. Patients with abnormal liver and kidney function; 3. TNM stage II and above; 4. History of ovarian surgery, hysterectomy, pelvic surgery or radiation therapy; 5. Pregnancy; 6. Have the following uterine abnormalities, such as uterine malformation (single-horned uterus, double uterus); untreated mediastinal uterus, submucosal uterine fibroids, multiple endometrial polyps, or severe uterine adhesion. 7. Patients diagnosed with polycystic ovary syndrome by the Rotterdam standard; 8. Patients with ovarian failure; 9. Patients have infectious factors, immune diseases and metabolic diseases that may affect pregnancy outcomes; 10. Pregnancy contraindications or diseases that have a clear impact on pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
AMH levelbefore treatment and 3, 6, 12 and 24 months after treatmentMeasure the concentration of AMH in serum

Secondary

MeasureTime frameDescription
Thyroid functionbefore tratment and 3, 6, 12 and 24 months after treatmentMeasure the level of TSH、T3、T4、FT3、FT4、TGAB、TPOAB in serum
clinical pregnancy rateup to 24 months after the treatmentClinical pregnancy is defined as the detection of intrauterine gestational sac through ultrasound, and the clinical pregnancy rate is calculated by clinically pregnant women/total women.

Countries

China

Contacts

Primary ContactMinghua Ge
tingtingzhou2019@163.com86+15673187412

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026